New RSV shot shows promise for vulnerable babies

NCT ID NCT06042049

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety and how the body processes two doses of nirsevimab, a medicine to prevent RSV, given 5 to 6 months apart. It included 33 Japanese infants up to 12 months old with heart or lung disease, weak immune systems, Down syndrome, or who were born early. Researchers checked for side effects and measured drug levels in the blood to ensure the medicine works well in these high-risk babies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease congenital heart disease Down syndrome immunodeficiency disease respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Bunkyō City, 113-8519, Japan

  • Research Site

    Fuchu-shi, 183-8561, Japan

  • Research Site

    Fukuoka, 813-0017, Japan

  • Research Site

    Kitakyusyu-shi, 806-8501, Japan

  • Research Site

    Kōtoku, 135-8577, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Nagasaki, 852-8501, Japan

  • Research Site

    Saitama-shi, 336-8522, Japan

  • Research Site

    Yokohama, 232 8555, Japan